TW200406402A - 3,4-Dihydroquinolin-2(1H)-one compounds as NR2B receptor antagonists - Google Patents

3,4-Dihydroquinolin-2(1H)-one compounds as NR2B receptor antagonists Download PDF

Info

Publication number
TW200406402A
TW200406402A TW092109786A TW92109786A TW200406402A TW 200406402 A TW200406402 A TW 200406402A TW 092109786 A TW092109786 A TW 092109786A TW 92109786 A TW92109786 A TW 92109786A TW 200406402 A TW200406402 A TW 200406402A
Authority
TW
Taiwan
Prior art keywords
disease
pain
compound
pharmaceutically acceptable
compounds
Prior art date
Application number
TW092109786A
Other languages
English (en)
Chinese (zh)
Inventor
Mitsuhiro Kawamura
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of TW200406402A publication Critical patent/TW200406402A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW092109786A 2002-04-26 2003-04-25 3,4-Dihydroquinolin-2(1H)-one compounds as NR2B receptor antagonists TW200406402A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37593902P 2002-04-26 2002-04-26

Publications (1)

Publication Number Publication Date
TW200406402A true TW200406402A (en) 2004-05-01

Family

ID=29270728

Family Applications (1)

Application Number Title Priority Date Filing Date
TW092109786A TW200406402A (en) 2002-04-26 2003-04-25 3,4-Dihydroquinolin-2(1H)-one compounds as NR2B receptor antagonists

Country Status (15)

Country Link
US (1) US6713490B2 (enExample)
EP (1) EP1499606B8 (enExample)
JP (1) JP2005524696A (enExample)
AR (1) AR039663A1 (enExample)
AT (1) ATE325117T1 (enExample)
AU (1) AU2003219398A1 (enExample)
BR (1) BR0309778A (enExample)
CA (1) CA2483636A1 (enExample)
DE (1) DE60305026T2 (enExample)
ES (1) ES2258716T3 (enExample)
MX (1) MXPA04010549A (enExample)
PA (1) PA8572601A1 (enExample)
TW (1) TW200406402A (enExample)
UY (1) UY27776A1 (enExample)
WO (1) WO2003091241A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3693258B2 (ja) 1996-07-24 2005-09-07 ワーナー―ランバート・コンパニー イソブチルｇａｂａまたはその誘導体を含有する鎮静剤
BRPI0415113A (pt) * 2003-10-08 2006-11-28 Pfizer compostos de lactama condensados
ES2246687B2 (es) * 2004-02-11 2006-11-16 Miguel Muñoz Saez Utilizacion de antagonistas no peptidicos de receptores nk1 para la produccion de apoptosis en celulas tumorales.
JPWO2005097782A1 (ja) * 2004-04-07 2007-08-16 協和醗酵工業株式会社 ピペリジン誘導体
HU226977B1 (en) * 2004-07-29 2010-04-28 Richter Gedeon Nyrt Kynurenic acid amide derivatives, pharmaceutical compositions containing them and process for producing them
US9744137B2 (en) * 2006-08-31 2017-08-29 Supernus Pharmaceuticals, Inc. Topiramate compositions and methods of enhancing its bioavailability
US8008253B2 (en) * 2007-07-03 2011-08-30 Andrew Tasker Treatment for anxiety
SG176464A1 (en) 2008-05-09 2011-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
AU2009296457A1 (en) 2008-09-27 2010-04-01 Taraxos Inc. Topical formulations for treatment of neuropathy
US20120077883A1 (en) * 2009-03-31 2012-03-29 De Barros Coelho Claudia Couto Treatment of tinnitus and associated auditory dysfunctions
WO2011145062A1 (en) 2010-05-21 2011-11-24 Link Research & Grants Corporation Treatment of tinnitus and related auditory dysfunctions
WO2012042314A1 (en) 2010-10-02 2012-04-05 Link Research & Grants Corporation Treatment of tinnitus and related auditory dysfunctions
US9387212B2 (en) 2012-04-20 2016-07-12 Ucb Biopharma Sprl Methods for treating Parkinson's disease
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902695A (en) 1989-02-13 1990-02-20 Eli Lilly And Company Excitatory amino acid receptor antagonists
RU2068414C1 (ru) 1990-05-10 1996-10-27 Пфайзер Инк. Производные индолона в виде рацемата или оптически активного изомера или их фармацевтически приемлемые аддитивные соли кислоты и кетопроизводные индолона
NZ255074A (en) 1992-10-30 1996-10-28 Pfizer 6-[2-(4-hydroxy-4-(4-substituted phenyl)piperidino)-1-hydroxypropyl]-3,4-dihydro-2(1h)-quinolones
US6407235B1 (en) 2000-08-21 2002-06-18 Hoffmann-La Roche Inc. Prodrug acid esters of [2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethansulfonyl]phenol

Also Published As

Publication number Publication date
AU2003219398A1 (en) 2003-11-10
ATE325117T1 (de) 2006-06-15
BR0309778A (pt) 2005-03-08
EP1499606B8 (en) 2006-08-30
EP1499606A1 (en) 2005-01-26
EP1499606B1 (en) 2006-05-03
US6713490B2 (en) 2004-03-30
ES2258716T3 (es) 2006-09-01
WO2003091241A1 (en) 2003-11-06
DE60305026D1 (de) 2006-06-08
CA2483636A1 (en) 2003-11-06
DE60305026T2 (de) 2006-10-12
PA8572601A1 (es) 2004-12-16
MXPA04010549A (es) 2005-02-17
AR039663A1 (es) 2005-03-02
US20030216430A1 (en) 2003-11-20
UY27776A1 (es) 2003-11-28
JP2005524696A (ja) 2005-08-18

Similar Documents

Publication Publication Date Title
WO2016169504A1 (zh) 稠环嘧啶氨基衍生物﹑其制备方法、中间体、药物组合物及应用
US9802945B2 (en) Imidazopyridazine derivatives as modulators of the GABAA receptor activity
CN108395452A (zh) 作为钠通道调节剂的吡啶酮酰胺的前药
TW200406402A (en) 3,4-Dihydroquinolin-2(1H)-one compounds as NR2B receptor antagonists
CN109071426A (zh) 取代的苯甲酰胺及其使用方法
US20040204409A1 (en) Bicyclic compounds as NR2B receptor antagonists
JP2017528503A (ja) 新規化合物αｖβ６インテグリンアンタゴニスト
JPH10279578A (ja) 新規なアリールピペリジン化合物、その製造法、及びそれらを含む医薬組成物
TW200902532A (en) Aza-pyridopyrimidinone derivatives
CN108601775A (zh) 阿片受体配体和细胞色素p450抑制剂的组合
CN114409658B (zh) 一种同时调节btk和ikzf3的双功能化合物
TW201206435A (en) Piperidinyl compound as a modulator of chemokine receptor activity
JP2007508288A (ja) 縮合ラクタム化合物
WO2017198180A1 (zh) 一类含氟三氮唑并吡啶类化合物及其制备方法、药物组合物和用途
TW200927090A (en) Novel sulfamate compounds for medical use
EP3105207A1 (en) Gpr142 agonist compounds
CN108727416A (zh) 三环杂芳香体系酰胺衍生物及其制备和用途
TW201245197A (en) Substituted [(5h-pyrrolo[2,1-c][1,4]benzodiazepin-11-yl)piperazin-1-yl]-2,2-dimethylpropanoic acid compounds as dual activity H1 inverse agonists/5-HT2A antagonists
CN110511173B (zh) 一种吲哚烷基哌嗪苯甲酰胺类化合物及其应用
CN116903571B (zh) 一种异黄酮化合物或其药物学上的盐的用途
CN116891447B (zh) 一类trpv1拮抗剂、制备方法及其在制备治疗疼痛药物中的应用
CN116023336A (zh) 一种具有Nav1.7钠离子通道靶向抑制作用的化合物及其药物组合物和用途
JPH11189585A (ja) ５−ｈｔ７受容体結合能を有するテトラヒドロベンズインドール誘導体
HK40065215A (en) Difunctional compound for simultaneously regulating btk and ikzf3
HK40065215B (en) Difunctional compound for simultaneously regulating btk and ikzf3